

# THE UNIVERSITY of EDINBURGH

### Edinburgh Research Explorer

### **Computed Tomography and Cardiac Magnetic Resonance in** Ischemic Heart Disease

### Citation for published version:

Dweck, MR, Williams, MC, Moss, A, Newby, DE & Fayad, ZA 2016, 'Computed Tomography and Cardiac Magnetic Resonance in Ischemic Heart Disease' Journal of the American College of Cardiology, vol. 68, no. 20, pp. 2201-2216. DOI: 10.1016/j.jacc.2016.08.047

#### **Digital Object Identifier (DOI):**

10.1016/j.jacc.2016.08.047

#### Link:

Link to publication record in Edinburgh Research Explorer

**Document Version:** Publisher's PDF, also known as Version of record

**Published In:** Journal of the American College of Cardiology

#### **General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY © 2016 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY LICENSE (http://creativecommons.org/licenses/by/4.0/).

#### THE PRESENT AND FUTURE

#### STATE-OF-THE-ART REVIEW

## Computed Tomography and Cardiac Magnetic Resonance in Ischemic Heart Disease



Marc R. Dweck, MD, PHD,<sup>a,b,c</sup> Michelle C. Williams, MD, PHD,<sup>c</sup> Alastair J. Moss, MD,<sup>c</sup> David E. Newby, MD, PHD,<sup>c</sup> Zahi A. Fayad, PHD<sup>a,b</sup>

#### ABSTRACT

Ischemic heart disease is a complex disease process caused by the development of coronary atherosclerosis, with downstream effects on the left ventricular myocardium. It is characterized by a long preclinical phase, abrupt development of myocardial infarction, and more chronic disease states such as stable angina and ischemic cardiomyopathy. Recent advances in computed tomography (CT) and cardiac magnetic resonance (CMR) now allow detailed imaging of each of these different phases of the disease, potentially allowing ischemic heart disease to be tracked during a patient's lifetime. In particular, CT has emerged as the noninvasive modality of choice for imaging the coronary arteries, whereas CMR offers detailed assessments of myocardial perfusion, viability, and function. The clinical utility of these techniques is increasingly being supported by robust randomized controlled trial data, although the widespread adoption of cardiac CT and CMR will require further evidence of clinical efficacy and cost effectiveness. (J Am Coll Cardiol 2016;68:2201-16) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

I schemic heart disease is a complex chronic disease characterized by pathological changes in both the coronary arteries and the myocardium, and which incorporates multiple different phases and clinical syndromes. Modern noninvasive imaging with computed tomography (CT) and cardiac magnetic resonance (CMR) now has the ability to monitor each of these different stages. In particular, CT allows precise imaging of coronary atherosclerosis (plaque burden, angiography, adverse plaque characteristics), whereas CMR allows detailed investigation of the left ventricle (perfusion, infarct visualization, function), although this distinction is increasingly becoming blurred with technological advances. This paper provides a comprehensive review of CT and CMR imaging in ischemic heart disease and compares their relative merits and limitations. Discussion examines their current clinical application and future potential developments, as well as the substantial barriers that exist to widespread adoption.

#### PATHOPHYSIOLOGY OF ISCHEMIC HEART DISEASE

Coronary atherosclerosis is a chronic progressive disease with a long and mostly unrecognized



Listen to this manuscript's audio summary by *JACC* Editor-in-Chief Dr. Valentin Fuster.



From the <sup>a</sup>Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; <sup>b</sup>Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; and the <sup>c</sup>Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom. Drs. Dweck and Newby are supported by British Heart Foundation awards (SS/CH/09/002/26360, FS/13/77/30488, SS/CH/09/002/2636, FS/14/78/31020, and CH/09/002). Dr. Newby is the recipient of Wellcome Trust Senior Investigator award WT103782AIA. Dr. Dweck is the recipient of a Sir Jules Thorn Award for Biomedical Research 2015. Dr. Fayad is supported by U.S. National Institutes of Health/National Heart, Lung, and Blood Institute awards NHLBI R01 HL071021, NIH/NHLBI R01 HL128056, NIH/NBIB R01 EB009638, and American Heart Association award 14SFRN20780005. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Prof. Dr. Stephan Achenbach, MD, served as Guest Editor for this paper.

Manuscript received June 20, 2016; revised manuscript received August 1, 2016, accepted August 5, 2016.

#### ABBREVIATIONS AND ACRONYMS

ACS = acute coronary syndrome

CAC = coronary artery calcium

CMR = cardiac magnetic resonance

CTA = computed tomography angiography

FFR = fractional flow reserve LGE = late gadolinium

enhancement

MI = myocardial infarction

**SPECT** = single-photon emission computed tomography preclinical phase. The first pathological abnormality, the fatty streak, can be observed as early as the second decade of life (1). Ultimately, these streaks develop into mature atherosclerotic plaques consisting of a central lipid core covered by a fibrous cap. As the plaque grows, the affected vessel expands in an outward direction, preserving both the luminal diameter and blood flow, in a process known as positive remodeling. Consequently, even large plaques can be accommodated without producing symptoms and without being identified on invasive angiography or stress testing. Eventually, the plaque begins to grow into the lumen of the vessel, obstructing blood flow and causing

myocardial ischemia and symptoms of angina pectoris. Importantly, although the degree of luminal stenosis is closely related to the development of myocardial ischemia, multiple other factors such as entrance effects, friction, and turbulence, also contribute to increased flow resistance across a particular stenosis (2). Moreover, it is now well established that most myocardial infarctions (MIs) arise from plaques that are nonobstructive on antecedent angiography, in part related to the much greater prevalence of these lesions (3,4).

Atherosclerotic plaques can remain quiescent for years; indeed, most will remain subclinical during a patient's lifetime. However, individual plaques can have a major clinical impact when their surface becomes disrupted, initiating thrombus formation and, potentially, vessel occlusion and acute coronary syndromes (ACS). Most commonly, ACS is triggered by acute fibrous cap rupture, which exposes the thrombogenic, tissue factor-rich lipid core to circulating blood. Alternatively, plaque erosion of the endothelium overlying the fibrous cap can lead to the formation of a platelet-rich thrombus, accounting for up to 30% of MIs (5). However, ACS is not an inevitable consequence of fibrous cap disruption. Indeed, subclinical plaque rupture appears common, with up to 70% of obstructive coronary plaques containing histological evidence of previous rupture and subsequent repair (6). The magnitude of the thrombotic response to plaque disruption is therefore also important and is governed by multiple factors, including the thrombogenicity of the blood, flow along the vessel, and constituents of the plaque.

Plaques that rupture and precipitate acute thrombotic events frequently have certain key characteristics on histological examination, including a thin fibrous cap (<65  $\mu$ m), positive remodeling, a large necrotic core, inflammation, microcalcification, angiogenesis, and plaque hemorrhage. Each of these adverse plaque characteristics, therefore, represents a potential imaging target for identifying plaques at high risk of rupture. Although prospective data have suggested that most of these so-called vulnerable plaques either heal or rupture subclinically rather than cause ACS (7), such features rarely exist in isolation and can serve as a marker of patients with advanced and metabolically active atheroma (7,8). Invasive imaging studies have demonstrated the presence of multiple high-risk plaques across the coronary vasculature in patients with ACS (9), and postmortem studies have demonstrated that multiple coronary thrombotic events are present at the time of fatal MIs (10). Both of these observations support a pancoronary vulnerability to atherosclerotic plaque rupture. On this basis, interest persists in detecting vulnerable plaque, not because these lesions will necessarily rupture themselves (11), but rather as a means of identifying vulnerable patients, those subjects with active atheroma and a propensity to develop multiple high-risk plaques over time, one of which may ultimately cause an event.

Both myocardial ischemia and infarction can have a profound effect on the structure and function of the left ventricular myocardium. MI results in tissue necrosis and ultimately irreversible areas of scarring, reducing the ability of the heart to both contract and relax. MI also results in areas of stunned myocardium, regions of hypokinesia that are damaged but not infarcted, with the potential to regain function. Similarly, severe myocardial ischemia can result in hibernating myocardium, areas with impaired function that can be restored if blood flow is improved. Ultimately, these insults to cardiac function can lead to congestive cardiac failure and development of ischemic cardiomyopathy.

#### IMAGING WITH CT AND CMR

The successful application of CT and CMR imaging to the heart was delayed compared with application to static organ systems, principally due to the heart's complex motion during both the cardiac and the respiratory cycles. However, advances in scanner technology now offer robust methods for motion correction and much improved spatial and temporal resolution, heralding a new era of noninvasive cardiac imaging. Each technology has different strengths and weaknesses (Table 1) that can potentially provide complementary information regarding ischemic heart disease. We focus here on the ability of these technologies to image plaque burden, high-risk plaque characteristics, and luminal stenoses in the coronary arteries, whereas in the left ventricle, we concentrate on the imaging of myocardial perfusion, infarction, viability, and function (**Central Illustration**).

#### CORONARY PLAQUE BURDEN

Coronary plaque burden assessments are useful in identifying the subclinical phase of the disease and providing powerful prediction of adverse cardiovascular events. Although most patients identified on imaging as having coronary atherosclerotic plaque do not subsequently suffer adverse events, the more plaques a subject has, the higher their risk, presumably because this increases the chances of 1 plaque becoming disrupted and causing an event. Imaging plaque burden is, therefore, potentially attractive in terms of both population screening and risk stratification of asymptomatic patients.

Coronary artery calcium (CAC) scoring uses noncontrast electrocardiographic (ECG)-gated CT to provide accurate and simple measurements of the coronary atherosclerotic burden (Figure 1). In particular, CAC quantifies macroscopic calcium within these vessels by using the Agatston score (12). Coronary macrocalcification is highly specific for atherosclerosis but is usually associated with stable plaques at low risk of rupture. This is supported by autopsy and imaging studies demonstrating that stable plaques are associated with advanced macroscopic calcification, whereas ruptured coronary plaques tend to be associated with the very early stages of micro- or spotty calcification (often with extensive calcification elsewhere in the coronary vasculature) (13-15). Similarly, other CT studies have demonstrated that more dense coronary calcification is associated with a lower risk of cardiovascular events than less dense calcium (16). Nevertheless, CT calcium scoring provides powerful prognostic information because it provides a surrogate for the total plaque burden that will correlate with the number of unstable, adjacent plaques. A CAC score >300 Agatston units (AU) is associated with a 4-fold higher risk of cardiovascular events than a CAC score of zero (17), which is itself associated with an excellent prognosis. Indeed, "the power of zero" is so good that it can provide a <1% annual mortality rate for up to 15 years in asymptomatic and otherwise low- or intermediaterisk patients (18), justifying the downscaling of preventive treatments (19). High calcium scores are also of use, with several population-based studies demonstrating that addition of calcium scoring to Framingham risk scores (20,21) improves the prediction of coronary events. On that basis, the 2013


Parameters*	ст	CMR
Scan acquisition		
Scan duration	0.5-10 s	10-20 min
Spatial resolution	Submillimeter	Millimeter
Temporal resolution	280–420 ms (as good as 65 ms with dual source CT)	<60 ms
Radiation exposure	1-10 mSv (depending on protocol)	No radiation exposure
Advantages	<ul> <li>Shorter total scan time</li> <li>Favored by patients</li> <li>Increased number of scans per day</li> <li>Single breath hold</li> <li>Better spatial resolution</li> </ul>	Radiation-free imaging • Serial scans • Young patients • Early disease Soft tissue characterization
Limitations	Requirement for adequate rate control Contrast medium reactions (iodine) Contrast induced nephropathy Calcium-related artifacts (the combination of partial volume averaging and photon starvation† makes calcium appear larger on CT) Radiation exposure	Claustrophobia Contrast medium reactions (gadolinium) Risk of nephrogenic systemic fibrosis if glomerular filtration rate <30 ml/min/1.73 m <sup>2</sup> Metallic implants (including pacemakers and automatt implantable cardioverter- defibrillators) Long scan times and limited spatial resolution

\*imaging parameters depend on the sequence performed. Typical values for coronary angiography are provided for comparison. †Photon starvation refers to a common artifact seen in the imaging of high attenuation structures, such as calcium.

CMR = cardiac magnetic resonance; CT = computed tomography.

American College of Cardiology/American Heart Association Guideline on the Management of High Cholesterol (22) recommended that a CAC score of >300 AU be used as a modifier to justify statin therapy for primary prevention in adults between 40 and 75 years of age without diabetes and with low-density lipoprotein cholesterol 70 to 189 mg/dl. Although the radiation dose associated with CT calcium scoring is small (2 to 3 mSv), it does remain of concern in the context of multiple repeat assessments or widespread population-based screening programs. Additionally, CT calcium scoring does not quantify the burden of noncalcified plaque, leading to interest in the use of contrast CT imaging. This allows measurement of the total coronary plaque burden, which also provides important prognostic information, refining the prediction of cardiac death and recurrent MI in intermediate-risk patients (23).

CMR black-blood imaging exploits differences in magnetic relaxation properties to generate soft tissue contrast and to differentiate atherosclerotic plaque from the surrounding lumen and extravascular tissues. This approach has become well established in the large and relatively immobile carotid arteries, providing detailed information about the presence, burden, and composition of atherosclerotic plaque (24). However, translation of black-blood plaque imaging to the




Both CT and CMR offer detailed and comprehensive imaging of ischemic heart disease. Gold-outlined boxes highlight preferred modalities. CT currently holds the advantage for coronary imaging, whereas CMR offers more detailed assessments of the myocardium. **Orange areas** on the coronary CTA outline areas of low attenuation (<30 Hounsfield units) plaque. **Orange arrow** on T1 weighted images indicates an area of high intensity plaque in the coronary arteries. **Orange arrows** on the perfusion images indicate areas of reduced myocardial perfusion during stress. **Orange arrows** on the late enhancement images indicate areas of subendocardial late enhancement consistent with previous myocardial infarction. CMR = cardiac magnetic resonance; CT = computed tomography; MRA = magnetic resonance angiography; MRI = magnetic resonance imaging.

coronary arteries has proved challenging. Indeed, although coronary plaque assessments are possible in individual lesions or arteries (25) (Central Illustration), more complete plaque assessments across the coronary vasculature as a whole remain elusive and the subject of ongoing research (26).

#### ADVERSE PLAQUE CHARACTERISTICS

Coronary CT angiography (CTA) is performed using contrast-enhanced imaging (**Figure 1**) and can offer detailed visualization and characterization of coronary atherosclerotic plaque, with good agreement






Coronary CTA allows assessment of both luminal stenosis and plaque constituents, calcific and noncalcific. Patient #1 shows matched CT calcium scoring (orange areas indicate calcium) (A) and coronary CTA images (B). Patient #2 shows matched CT calcium scoring (C) and coronary CTA images (D). Patient #3 shows invasive coronary angiogram (E) and coronary CTA (F), demonstrating a stenosis in the proximal left anterior descending artery. Coronary MRA provides luminal assessments of the proximal right coronary artery (G) and demonstrates aberrant origins of both the left anterior descending and the circumflex arteries from the right coronary sinus (arrows) (H). CTA = computed tomography angiography; other abbreviations as in Central Illustration.

compared to intravascular ultrasonography (Figure 1) (27,28). Iodinated contrast is injected through a peripheral cannula, and imaging is timed to ensure peak contrast enhancement of the coronary vessels. Prospective ECG triggering or retrospective ECG gating is used during a single breathhold. Use of 64-multidetector scanners produces images of the heart composed of a number of sections, whereas scanners with more detectors (256 to 320) and a wider z-axis dimension can acquire images of the entire cardiac volume within a single rotation.

Clinically, coronary CTA is widely used to categorize individual plaques as noncalcified (no calcium density), calcified (entire plaque appears as calcium density), or partially calcified (2 visible plaque components, 1 of which is calcified) (29). Beyond this simple categorization, coronary CTA has demonstrated its ability to identify a range of adverse plaque characteristics, including positive remodeling, necrotic core, napkin ring sign, and spotty calcification (**Figure 2**) (30). Positive remodeling is defined by eccentric plaque formation with relative preservation of the lumen caliber. Regions of low-attenuation plaque (commonly <30 HU) identify a large necrotic core, whereas the napkin ring sign is a CT signature of low attenuation surrounded by a rim of high attenuation. Spotty calcification has been described as a marker of early atherosclerotic calcification (although not true microcalcification) and is also an adverse plaque characteristic (14). Improvements in CT postprocessing appear to improve further the delineation of noncalcified plaque, facilitating more accurate assessment of plaque composition (31).

Importantly, several studies have demonstrated that each of these adverse plaque characteristics is more common in patients with ACS than in those with stable angina (14,32). Moreover, recent data indicate that the prospective identification of these features can identify subjects at increased risk of subsequent ACS. Motoyama et al. (33) studied 3,158 patients with coronary CTA and found high-risk lesions (defined by the presence of both positive remodeling and lowattenuation necrotic cores) in 294 patients who were subsequently 10 times more likely to experience ACS than patients without such plaque (16% event rate in patients with high-risk plaque compared with 1.4% event rate in those without). Similarly, a recent metaanalysis showed that the risk of future ACS was



12-fold higher (odds ratio: 12.1; 95% confidence interval [CI]: 5.2 to 28.1; p < 0.0001) in patients with high-risk lesions than in those with low-risk plaques (30). Although these data support adverse plaque detection as a means of identifying high-risk patients, confirmation in large-scale multicenter clinical trials is required. A current limitation to more widespread use is that the visual assessment of adverse plaque features is both subjective and time consuming; thus, the development of accurate, automated quantification methods is keenly anticipated (34).

The superior soft tissue characterization offered by CMR compared with that of CT is potentially well suited to the detection of adverse plaque characteristics. CMR provides the gold standard characterization of carotid atherosclerotic plaque (24); however, once again, translation of this technology to the coronary arteries has proved challenging. Although the black-blood sequences described earlier can be used to identify positive remodeling (35), only a small proportion of the coronary vasculature can be sampled, and approximately one third of these areas then proves uninterpretable.

CMR approaches aimed at detecting methemoglobin as a marker of acute coronary thrombus are at a more advanced stage of development. Methemoglobin is an intermediate breakdown product of hemoglobin formed 12 to 72 h after hemorrhage or thrombus formation and therefore represents a key component of these acute events. Methemoglobin is associated with a high signal and short T1, allowing fresh thrombi to be detected on CMR in a range of situations, including coronary plaque disruption and intraplaque hemorrhage (Figure 2). In post-MI patients, T1-weighted imaging detected thrombus at the site of the culprit coronary plaque with a sensitivity and specificity of  $\sim 90\%$  (36). In patients with angina, this approach identifies plaque with multiple adverse features on other imaging modalities (37,38). T1-weighted CMR imaging also appears to provide important prognostic information. In a recent study, high-intensity plaques were observed in 159 of 568 patients with known or suspected coronary artery disease. Forty-one of these subjects subsequently experienced a coronary event, with the presence of a high-intensity plaque acting as an independent predictor on multivariate analysis (hazard ratio [HR]: 3.96; 95% CI: 1.92 to 8.17) (39). A major advantage of this technique compared with other CMR approaches is that these sequences acquire information across the entire volume of the heart and are therefore not limited by sampling error. However, they lack anatomic information, so they must be fused with CMR angiographic scans (Figure 2). Although it is a promising approach, large multicenter studies are required before noncontrast T1-weighted coronary imaging can be recommended clinically.

#### CORONARY ANGIOGRAPHY

Invasive angiography offers unparalleled spatial and temporal resolution. Combined with intravascular ultrasonography and optical coherence tomography, angiography remains the gold-standard for assessing coronary luminal stenoses. It is supported by extensive clinical experience and research data that have confirmed the progressive deterioration in prognosis associated with 1-, 2-, or 3-vessel coronary disease (40). Moreover, it offers the unique opportunity to perform percutaneous coronary intervention immediately after imaging. However, this form of imaging is resource-intensive, invasive, and associated with a small incidence of complications. Additionally, 60% of diagnostic angiograms fail to demonstrate the obstructive coronary disease anticipated (41). The use of noninvasive coronary angiography as a "gatekeeper" to improve patient selection for the catheter laboratory is therefore of major interest.

Coronary CTA demonstrates excellent diagnostic accuracy for the detection of obstructive luminal stenoses compared with invasive coronary angiography. Indeed, a recent meta-analysis described a sensitivity of 93% and specificity of 96% for coronary CTA on a per-segment basis to detect stenoses of >50% (42). Although results in multicenter settings are slightly inferior (sensitivity of 85%, specificity of 90% on a per-vessel basis) (43), they remain sufficient for clinical use. One consistent finding across all trials is the excellent negative predictive value of coronary CTA (>95%) (44), making this technique extremely useful for the exclusion of coronary artery disease. Although rates of nonassessable segments are low (0% to 11%) (45), they are still observed, and commonly relate to motion in the right coronary artery at faster heart rates or partial volume artifact from dense calcification or coronary artery stents (46). It is therefore critical that adequate heart rate control (<65 beats/min) is achieved by using betablockade administration. Advancements in scanner hardware and software, including faster scanners, wider detector arrays, increased spatial resolution, new reconstruction algorithms, motion correction algorithms, and dual-source imaging, may further reduce these artifacts (47). Although coronary CTA is, by necessity, associated with radiation exposure, this has been reduced substantially and is now routinely lower than nuclear imaging modalities. For example, in SCOT-HEART, the median radiation dose for CT imaging, including coronary CTA and CAC scoring, was 4.1 (3.0 to 5.6 mSv) (48).

Coronary CTA assessments of coronary artery stenosis provide important prognostic information. Similar to coronary angiography, a stepwise deterioration in prognosis associated with 1-, 2-, and 3-vessel disease has been observed using coronary CTA (49). Coronary CTA has also documented the adverse prognosis associated with nonobstructive disease (not detected with standard perfusion assessments) and confirmed the excellent prognosis for patients with a normal coronary CTA, with a risk of cardiovascular events of <0.5% that extends up to 5 years (50). Coupled with the excellent negative predictive value of a normal scan, coronary CTA is recommended in ruling out coronary artery disease in those considered at low or intermediate risk (51).

Recently, 2 large multicenter randomized controlled trials (RCTs) have assessed the utility of outpatient coronary CTA in patients with stable chest pain. The PROMISE (PROspective Multicenter Imaging Study for Evaluation of chest pain) trial randomized 10,003 symptomatic stable outpatients to initial evaluation with coronary CTA or to functional testing (52). Patients were a mean 62 years of age, 53% were female, and the pre-test probability of obstructive coronary artery disease was 53%. There were no differences in outcomes between the 2 strategies at 25 months follow-up, indicating that coronary CTA can provide effective risk stratification and be safely used in the management of outpatients with suspected coronary heart disease. The SCOT-HEART study used a different strategy, randomizing 4,146 outpatients with suspected angina due to coronary

heart disease to standard care (including high rates of stress testing) or standard care plus coronary CTA. Patients were a mean 58 years of age, 44% were female, and the pre-test probability of obstructive congenital heart disease was 47%. The addition of coronary CTA provided improved diagnostic certainty and reduced rates of normal coronary angiography. Post hoc analysis showed that coronary CTA led to more appropriate use of revascularization and preventive therapies associated with a halving of fatal and nonfatal MI (48,53). Reduced MI rates among stable patients assessed with coronary CTA versus standard care were also observed in a recent meta-analysis including >14,000 patients (54).

Several RCTs have also assessed the clinical utility of coronary CTA in patients who attend the emergency department with acute chest pain (CT-STAT [Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment], ROMICAT-II [Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography], ACRIN-PA [CT Angiography for Safe Discharge of Patients with Possible Acute Coronary Syndromes]) (55-57), most of whom do not have ACS. These studies have demonstrated that early coronary CTA accelerates diagnosis and, as a consequence, expedites either discharge or initiation of therapy. A meta-analysis showed that coronary CTA reduced hospital stay and expenditure, while increasing rates of invasive coronary angiography and revascularization (58). On the basis of those studies, the use of coronary CTA in the assessment of patients with stable angina and in the emergency department has now entered routine clinical practice.

CMR angiography offers major technical challenges and, to date, has lagged behind coronary CTA. However, CMR angiography potentially holds several key advantages over CT, maintaining interest in this method (Figure 1) (26). First, CMR angiography is not affected by the calcium-related artifacts that can limit the utility of coronary CTA imaging in patients with advanced atheroma. Second, and perhaps most importantly, CMR angiography does not involve exposure to ionizing radiation. This is particularly attractive with respect to screening programs for the imaging of younger patients with earlier stage disease and for serial imaging to track disease progression over time. Indeed, it is worth noting that CMR, not CT, has emerged as the imaging modality of choice for assessing the carotid and peripheral arteries, with intense research focused on translating these same techniques to the coronary arteries.

It takes much longer to acquire CMR angiography data than CTA data, so imaging within a single breath-hold is not currently feasible. As a consequence, the major challenge facing CMR angiography is how to successfully correct for coronary arterial motion while acquiring sufficient information for high spatial resolution (26). Current sequences rely upon ECG gating coupled with a respiratory navigator so that CMR data are acquired only in diastole, when the diaphragm is close to its resting position. This approach is highly wasteful, with most of the data being ignored. Scans are therefore time consuming, and even the fastest CMR angiography sequences take  $\sim$ 10 min compared with the seconds or even milliseconds required for coronary CTA. Moreover, the metallic artifact that arises from intracoronary stents on CMR remain unresolved. Nevertheless, CMR angiography allows assessment of the proximal and midcoronary vessels with an accuracy approaching that of CTA (26). Kim et al. reported the first multicenter study to investigate the accuracy of CMR angiography compared to invasive angiography, demonstrating a sensitivity of 93% but a disappointing specificity of 42% for obstructive coronary artery disease (59). A subsequent metaanalysis in 2010 showed improvement, with an overall sensitivity of 87% and a specificity of 70% (60). With further technological advances, the latest techniques (noncontrast, free-breathing, 3dimensional whole-heart steady-state free precession scans) report further improvements in accuracy (sensitivity of 91%, specificity of 86%, area under the curve of 0.92), although this remains inferior to coronary CTA (61). Consequently, the most recent Appropriateness Use Criteria do not recommend the use of CMR angiography for the assessment of native coronary arteries (62). However, 2 areas where CMR angiography is recommended are in the assessment of anomalous coronary arteries with aberrant origins (Figure 1) and in the detection of coronary aneurysms. CMR angiography can provide accurate visualization of these proximal, large-caliber abnormalities and avoid radiation exposure in young patients, who are the most commonly affected.

### FLOW OBSTRUCTION AND MYOCARDIAL PERFUSION

Stenoses of the coronary vasculature can limit blood flow to the myocardium, resulting in ischemia and anginal symptoms during periods of increased demand (e.g., exercise). However, the degree of coronary stenosis and the extent of myocardial ischemia




image (I). Abbreviations as in Central Illustration.

do not correlate well; thus, noninvasive assessments of flow obstruction and myocardial perfusion retain an important role in patients with these symptoms.

CT can provide functional assessments of coronary flow obstruction by using 2 major approaches: myocardial perfusion imaging and noninvasive CT-derived fractional flow reserve ( $FFR_{CT}$ ). CT myocardial perfusion imaging involves assessment of the passage of iodinated contrast medium into the myocardium during vasodilator stress (e.g., adenosine, dypyridamole, or regadenoson) (**Figure 3**). Two different protocols have been established, namely, the "snapshot" and "dynamic" techniques. The "snapshot" protocol involves acquisition of 1 image (or a small number of images) at the peak of myocardial enhancement, limiting radiation exposure. Perfusion defects are identified as a comparison between areas of reduced myocardial attenuation density and normal or resting myocardium (**Figure 3**). The "dynamic" protocol obtains multiple images during both contrast wash-in and wash-out. This is similar to CMR or positron-emission tomography perfusion imaging, allowing calculation of myocardial blood flow. The largest multicenter study of CT perfusion imaging to date, the CORE320 (Computed tomography angiography and perfusion to assess coronary artery stenosis causing perfusion defects by single photon emission computed tomography) study, used the snapshot approach and demonstrated a sensitivity of 80% and specificity of 74% for the presence of obstructive coronary artery disease compared to single-photon emission computed tomography (SPECT) (63). A recent meta-analysis identified a pooled sensitivity of 75% to 84% and a specificity of 78% to 95%, depending on the protocol used (64). Although CT perfusion involves additional radiation exposure, it may find a useful role as an adjunct to coronary CTA in the presence of indeterminate stenoses.

Computational flow dynamics have been used to calculate FFR from coronary CTA images (FFR<sub>CT</sub>). Several multicenter studies have compared FFR<sub>CT</sub> with FFR assessed during invasive angiography (e.g., the DISCOVER-FLOW [Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve] and DeFACTO [Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography] studies) (65,66). A recent meta-analysis found that FFR<sub>CT</sub> had a pooled sensitivity similar to coronary CTA (0.83 vs. 0.86, respectively, per-vessel analysis) but improved specificity (0.78 vs. 0.56, respectively, per-vessel analysis) (67). Recently, the PLATFORM (Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts) study showed that FFR<sub>CT</sub> reduced the number of subsequently normal invasive coronary angiograms compared with standard care, reducing costs and improving quality of life (68). However, this study did not directly compare FFR<sub>CT</sub> with the results of coronary CTA alone, so the incremental benefits of FFR<sub>CT</sub> over those of CTA were not studied. Moreover, this form of image analysis is expensive, and it remains unclear how it deals with the problems of calcium artifacts and cardiac motion that often underlie indeterminate lesions.


CMR can detect myocardial ischemia by assessing both myocardial perfusion and changes in left ventricular wall motion in response to stress. CMR perfusion is most commonly performed at rest and peak vasodilator stress following the bolus administration of gadolinium. On first pass perfusion regions of myocardial ischemia are relatively hypoperfused, resulting in a reduced or delayed peak in the myocardial signal intensity (Figure 3). Reversible defects can then be differentiated from areas of MI, identified on rest perfusion or late gadolinium enhancement (LGE). CMR perfusion has been tested in several large clinical trials, demonstrating high diagnostic accuracy (69) that was at least equivalent to that of SPECT perfusion imaging in the recent CE-MARC (Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease) clinical trial (70). This trial also recently demonstrated that CMR perfusion provides prognostic information that is improved compared with that of SPECT (71). A recent large meta-analysis demonstrated a pooled sensitivity of 89% and a specificity of 78% for the detection of obstructive coronary artery disease (72) and that a negative CMR stress perfusion test was associated with an excellent prognosis (73). Although SPECT is much more widely available in the United States and supported by strong prognostic observational data, CMR perfusion has the crucial advantage of being radiation-free and appears to be cost effective (74). The 2013 European Society of Cardiology guidelines on the management of stable coronary artery disease recommend stress perfusion CMR as 1 potential imaging option for the assessment of patients presenting with chest pain and a pre-test probability of coronary artery disease of 15% to 85% (Class I recommendation; Level of Evidence: B) (51). CMR perfusion appears to be particularly clinically useful in patients with severe coronary artery disease when additional information related to myocardial viability and myocardial function can aid decision making. CMR perfusion therefore potentially complements coronary CTA, which, as discussed, is best used at the milder end of the disease spectrum.

Similar to stress echocardiography, CMR can detect obstructive coronary artery disease based upon the detection of wall motion abnormalities that develop in response to low-dose dobutamine stress (75). CMR perfusion imaging is usually preferred, perhaps due to concerns regarding inotrope administration in the scanner, although major complications appear to be rare (75).

### IMAGING MYOCARDIAL INFARCTION, VIABILITY, AND FUNCTION

The presence of persistent contrast on delayed imaging can be used to identify scarring or fibrosis in the left ventricular myocardium, using CMR and CT. Both iodinated CT contrast agents and gadolinium wash out of regions of replacement myocardial fibrosis or scarring more slowly than areas of normal healthy myocardium. Increased signal/attenuation are therefore observed in these areas if imaging is performed at delayed time points, informing about both the presence and pattern of myocardial scarring in the left ventricle.

The first description of MI detection using late enhancement was, in fact, made with CT in 1976 (76). More recently, CT late enhancement has demonstrated moderate diagnostic accuracy in the detection of MI (sensitivity of 52% to 78%, specificity of 88% to 100%) (77), with several techniques (e.g., low tube



voltage, dual-energy imaging, and increased contrast volume) being explored to improve scar visualization (78) (Figure 4). However, the inferior image quality and associated radiation exposure (1 to 5 mSv) mean that CMR late enhancement techniques are currently preferred.

Over the last 2 decades, LGE CMR has become the gold standard method for detecting myocardial scar. Indeed, the principal strength of CMR has been the

detailed myocardial tissue characterization it provides. Different pathologies demonstrate different patterns of scarring and, consequently, different patterns of LGE. For example, previous MI is associated with subendocardial LGE (the myocardial region farthest from the epicardial coronary arterial system) that extends transmurally as vessel occlusion persists (**Figure 4**). This can be clearly differentiated from the linear mid-wall pattern (or absence of LGE) observed in dilated cardiomyopathy, helping clinically to differentiate between these 2 pathologies (79). Similarly, in patients presenting with acute troponinpositive chest pain and nonobstructive coronary angiography, CMR can help differentiate between MI and other potential diagnoses such as myocarditis or Takotsubo cardiomyopathy (80).

Importantly, regardless of the pattern of fibrosis or the cardiac condition, the presence of myocardial LGE is consistently associated with an adverse prognosis (81,82). Following MI, multiple large studies have demonstrated that infarct size measured by CMR LGE is a stronger predictor of outcome than either left ventricular volumes or ejection fraction (83,84).

The detection of prior MI using LGE also appears more sensitive than previous techniques (e.g., ECG analysis and nuclear techniques), allowing us to appreciate the relatively high prevalence of unrecognized MI in at-risk populations. Kwong et al. (85) studied 195 patients (mean 59  $\pm$  13 years of age, 68% male) with symptoms or signs suspicious for ischemic heart disease but without a previous diagnosis of MI. They observed subendocardial MIs in 23% of their patients (n = 44), often involving only a small area of the myocardium (85). In the ICELAND-MI (Prevalence and Prognosis of Unrecognized Myocardial Infarction Determined by Cardiac Magnetic Resonance in Older Adults) study (86), 936 patients (mean 76 years of age, 48% male) underwent CMR, with 10% (n = 91) found to have previously unrecognized MI. In a subgroup of 377 diabetic patients, previously unrecognized MI was observed in more than 20% (n = 72) (86). Importantly, in each of these studies and others, the presence of previously unrecognized MI was a strong independent predictor of prognosis (85-87).

Aside from its prognostic utility, CMR LGE is increasingly being used clinically to assess myocardial viability. In 2000, Kim et al. (88) assessed the ability of LGE to predict functional recovery in hypokinetic areas of myocardium following revascularization (n = 50 patients and 804 hypokinetic segments) (Figure 4). In segments with  $\leq 25\%$  transmurality of scar, ~80% recovered function, whereas only 10% of segments recovered when the transmurality was >50% (88). This has been confirmed in several other small, single-center studies (89,90). A remaining difficulty is the segments with 25% to 50% transmurality, which demonstrate a roughly 50:50 chance of functional recovery, although in these cases, addition of a low-dose dobutamine study can help improve diagnostic accuracy (84). Measuring the thickness of viable tissue around the rim of the infarct provides an alternative assessment of viability, with measurements >4 mm associated with an increased likelihood of functional recovery (91,92). In contrast, myocardial wall thickness is not necessarily a reliable guide. Shah et al. (93) recently demonstrated that 18% of thinned (<5.5 mm) akinetic myocardial segments have evidence of only limited LGE (<50% transmurality) and that these regions frequently demonstrated improved contractility and resolution of thinning following revascularization (93). Despite the supportive observational data and the expanding clinical experience with LGE in assessing viability, definitive evidence demonstrating improved clinical outcome following CMR-guided revascularization remains lacking. This is urgently required, particularly given the failure of alternative viability assessments to improve prognosis in the STITCH (Surgical Treatment for Ischemic Heart Failure) trial (94).

CMR can provide myocardial tissue characterization beyond the presence of myocardial scar, with the ability to identify myocardial necrosis, edema, hemorrhage, microvascular obstruction, and left ventricular thrombus. This is of use in the early stages following acute MI, when scar has yet to develop but where LGE uptake still occurs in regions of myocardial necrosis and edema. Indeed, in these early stages following MI, LGE tends to overestimate the size of the scar that will ultimately develop. LGE imaging can also be used to detect microvascular obstruction. This appears as a dark core within the otherwise bright regions of late enhancement and is a feature of large transmural infarcts correlating with the angiographic no-reflow phenomenon and myocardial hemorrhage (Figure 4). In addition to infarct size, it heralds a poor prognosis for patients post MI of incremental value to standard predictors (84).

Other sequences can also be used to visualize acute MI. T2-weighted short-tau inversion recovery (STIR) imaging detects regions of myocardial edema, helping to differentiate acute from chronic infarction and to allow calculation of the myocardial area at risk (95). Novel T1 mapping techniques can go beyond LGE imaging to identify more diffuse, interstitial forms of fibrosis in the remote myocardium and peri-infarct area (96). Finally, early imaging, 1 to 4 min following gadolinium injection, allows detection of intracardiac thrombi with improved sensitivity (88%) compared with echocardiographic techniques (97,98) (**Figure 4**).

The assessment of global and regional function in the left ventricle is performed routinely using echocardiography. This provides important prognostic and diagnostic information in the assessment of patients with ischemic heart disease and is used to guide implantation of automatic implantable cardioverterdefibrillators and cardiac resynchronization therapy. In patients with poor echocardiographic windows or in cases of diagnostic uncertainty, CMR can be used to assess left ventricular function. Indeed, CMR is widely considered the noninvasive gold standard for these measurements (62). Similar assessments are also available with coronary CTA using images acquired throughout the cardiac cycle, although this again involves radiation exposure (3 to 10 mSv) and is rarely performed in clinical practice.

#### BARRIERS TO WIDESPREAD CLINICAL ADOPTION

CT and CMR offer detailed and comprehensive imaging of patients with ischemic heart disease. The prognostic implications of these assessments are now well established, with emerging studies demonstrating the ability of these modalities to change patient management and improve clinical outcomes, such as cardiac events and mortality. However, several barriers to their widespread clinical adoption remain. CT imaging will need to continue to reduce radiation doses, particularly in the context of perfusion, viability, and functional assessments. The use of CT in the emergency department will require rapid access to scanners and the availability of trained technologists and reporters. For patients with stable chest pain, there is currently a wide choice of noninvasive imaging modalities, with further work required in order to determine how best to incorporate CT within the patient care pathway. The development of noncontrast CMR approaches, faster imaging protocols, and CMR-compatible permanent pacemakers and automatic implantable cardioverter-defibrillators will also be important in increasing the clinical utility of this modality. Currently, CMR is a time-consuming process with respect to both image acquisition and interpretation. However, improvements in software, hardware, and, in particular, motion correction (removing the need for ECG gating) appear set to greatly improve the efficiency and accessibility of CMR. Concerns also exist about administration of gadolinium-based contrast medium. These agents are widely used in radiological practice, with overall an excellent safety profile (the incidence of acute adverse reactions is 0.1% to 0.2%). However, they should be avoided, if possible, in patients with advanced renal dysfunction (glomerular filtration rate <30 ml/min/1.73 m<sup>2</sup>), in whom the rare but serious complication of nephrogenic systemic fibrosis has been reported (99). Moreover, the accumulation of gadolinium in the brain after repeated administration has recently been described, even in patients with normal renal function (100). This led the U.S. Food and Drug Administration to issue a drug safety communication (101), although the clinical implications of this observation remain unclear.

Perhaps the major barrier to the widespread clinical adoption of cardiac CT and CMR is the relative expense and limited availability of these techniques. This is especially the case in the developing world, where the burden of ischemic heart disease is rising rapidly. However, even in the developed world, modalities such as ultrasonography and nuclear imaging are more accessible and can be performed at reduced cost. In the current era of constrained healthcare expenditure, advanced imaging techniques, such as CT and CMR, will therefore need to find ways to complement these existing approaches and to demonstrate not only their clinical superiority, but also their cost effectiveness.

#### CONCLUSIONS

CT and CMR imaging of the coronary arteries and left ventricular myocardium provides complementary and comprehensive assessments of ischemic heart disease from its earliest pre-clinical stages to the final phases of advanced cardiac failure. These novel imaging modalities are already affecting clinical care, with further advances set to expand their utility and role. In particular, CT has emerged as the noninvasive test of choice for imaging the coronary vasculature, demonstrating clinical efficacy in multiple large-scale RCTs. CMR, by contrast, is of major value in assessing the left ventricular myocardium, in particular, its ability to investigate myocardial perfusion and tissue composition without the need for ionizing radiation. With ongoing and rapid technological development, the clinical utility of both approaches is set to expand still further, although their widespread adoption will require further RCTs demonstrating improved clinical outcomes and cost-effectiveness.

**ACKNOWLEDGMENT** The authors thank Dr. Phillip Robson, Icahn School of Medicine at Mount Sinai, New York, for help in providing coronary magnetic resonance angiography images.

**REPRINT REQUESTS AND CORRESPONDENCE:** Dr. Zahi A. Fayad, Translational and Molecular Imaging Institute, Hess Building, 1st Floor, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, New York 10029. E-mail: zahi.fayad@mssm.edu.

#### REFERENCES

**1.** Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.

**2.** Kern MJ, Samady H. Current concepts of integrated coronary physiology in the catheterization laboratory. J Am Coll Cardiol 2010;55:173-85.

**3.** Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.

**4** Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013;368:2004–13.

**5.** Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996;93: 1354–63.

**6.** Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 1999;82:265-8.

**7.** Dweck MR, Aikawa E, Newby DE, et al. Noninvasive molecular imaging of disease activity in atherosclerosis. Circ Res 2016;119:330-40.

 Dweck MR, Doris MK, Motwani M, et al. Imaging of coronary atherosclerosis-evolution towards new treatment strategies. Nat Rev Cardiol 2016; 13:533-48.

**9.** Vergallo R, Ren X, Yonetsu T, et al. Pancoronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: a 3-vessel optical coherence tomography study. Am Heart J 2014;167:59-67.

**10.** Davies MJ, Bland JM, Hangartner JR, et al. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J 1989;10:203-8.

**11.** Arbab-Zadeh A, Fuster V. The myth of the "vulnerable plaque": transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. J Am Coll Cardiol 2015;65:846-55.

**12.** Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultraflash computed tomography. J Am Coll Cardiol 1990;15:827-32.

**13.** Otsuka F, Finn AV, Virmani R. Do vulnerable and ruptured plaques hide in heavily calcified arteries? Atherosclerosis 2013;229:34–7.

**14.** Motoyama S, Kondo T, Sarai M, et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol 2007;50:319–26.

**15.** Joshi NV, Vesey AT, Williams MC, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet 2014;383:705-13.

**16.** Criqui MH, Denenberg JO, Ix JH, et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA 2014;311: 271–8.

**17.** Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic

individuals. JAMA 2004;291:210-5. erratum: JAMA 2004;291:563.

**18.** Valenti V, ó Hartaigh B, Heo R, et al. A 15-year warranty period for asymptomatic individuals without coronary artery calcium: a prospective follow-up of 9,715 individuals. J Am Coll Cardiol Img 2015;8:900-9.

**19.** Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2015;66:1657-68.

**20.** Erbel R, Möhlenkamp S, Moebus S, et al., Heinz Nixdorf Recall Study Investigative Group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol 2010;56:1397-406.

**21.** Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediaterisk individuals. JAMA 2012;308:788-95.

**22.** Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-934.

**23.** Gitsioudis G, Schüssler A, Nagy E, et al. Combined Assessment of high-sensitivity troponin T and noninvasive coronary plaque composition for the prediction of cardiac outcomes. Radiology 2015;276:73-81.

**24.** Vesey AT, Dweck MR, Fayad ZA. Utility of combining PET and MR imaging of carotid plaque. Neuroimaging Clin N Am 2016;26:55-68.

**25.** Fayad ZA, Fuster V, Fallon JT, et al. Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation 2000;102:506-10.

**26.** Dweck MR, Puntman V, Vesey AT, et al. MR imaging of coronary arteries and plaques. J Am Coll Cardiol Img 2016;9:306-16.

**27.** Achenbach S, Moselewski F, Ropers D, et al. Detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, submillimeter multidetector spiral computed tomography: a segment-based comparison with intravascular ultrasound. Circulation 2004;109: 14-7.

**28.** Leber AW, Becker A, Knez A, et al. Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol 2006;47:672-7.

29. Weigold WG, Abbara S, Achenbach S, et al. Standardized medical terminology for cardiac computed tomography: a report of the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr 2011;5:136–44. **30.** Thomsen C, Abdulla J. Characteristics of highrisk coronary plaques identified by computed tomographic angiography and associated prognosis: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging 2016;17:120-9.

**31.** Zhao L, Plank F, Kummann M, et al. Improved non-calcified plaque delineation on coronary CT angiography by sonogram-affirmed iterative reconstruction with different filter strength and relationship with BMI. Cardiovasc Diagn Ther 2015;5:104–12.

**32.** Hoffmann U, Moselewski F, Nieman K, et al. Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J Am Coll Cardiol 2006;47:1655-62.

**33.** Motoyama S, Ito H, Sarai M, et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. J Am Coll Cardiol 2015;66:337-46.

**34.** Dey D, Schepis T, Marwan M, et al. Automated three-dimensional quantification of noncalcified coronary plaque from coronary CT angiography: comparison with intravascular US. Radiology 2010;257:516–22.

**35.** Terashima M, Nguyen PK, Rubin GD, et al. Right coronary wall CMR in the older asymptomatic advance cohort: positive remodeling and associations with type 2 diabetes and coronary calcium. J Cardiovasc Magn Reson 2010;12:75.

**36.** Jansen CHP, Perera D, Makowski MR, et al. Detection of intracoronary thrombus by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 2011;124: 416–24.

**37.** Ehara S, Hasegawa T, Nakata S, et al. Hyperintense plaque identified by magnetic resonance imaging relates to intracoronary thrombus as detected by optical coherence tomography in patients with angina pectoris. Eur Heart J Cardiovasc Imaging 2012;13:394–9.

**38.** Kawasaki T, Koga S, Koga N, et al. Characterization of hyperintense plaque with noncontrast T1-weighted cardiac magnetic resonance coronary plaque imaging. J Am Coll Cardiol Img 2009;2: 720-8.

**39.** Noguchi T, Kawasaki T, Tanaka A, et al. Highintensity signals in coronary plaques on noncontrast T1-weighted magnetic resonance imaging as a novel determinant of coronary events. J Am Coll Cardiol 2014;63:989-99.

**40.** Emond M, Mock MB, Davis KB, et al. Longterm survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994;90:2645-57.

**41.** Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography [Published correction appears in N Engl J Med 2010;363:498]. N Engl J Med 2010;362:886-95.

**42.** Vanhoenacker PK, Heijenbrok-Kal MH, Van Heste R, et al. Diagnostic performance of multi-detector CT angiography for assessment of

coronary artery disease: meta-analysis. Radiology 2007;244:419-28.

**43.** Miller JM, Rochitte CE, Dewey M, et al. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med 2008;359:2324-36.

**44.** Budoff MJ, Dowe D, Jollis JG, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. J Am Coll Cardiol 2008;52:1724-32.

**45.** Menke J, Kowalski J. Diagnostic accuracy and utility of coronary CT angiography with consideration of unevaluable results: a systematic review and multivariate Bayesian random-effects metaanalysis with intention to diagnose. Eur Radiol 2016;26:451–8.

**46.** Achenbach S, Manolopoulos M, Schuhbäck A, et al. Influence of heart rate and phase of the cardiac cycle on the occurrence of motion artifact in dual-source CT angiography of the coronary arteries. J Cardiovasc Comput Tomogr 2012;6: 91-8.

**47.** Danad I, Fayad ZA, Willemink MJ, et al. New applications of cardiac computed tomography: dual-energy, spectral, and molecular CT imaging. J Am Coll Cardiol Img 2015;8:710–23.

**48.** The SCOT-HEART Investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. Lancet 2015:385:2383-91.

**49.** Min JK, Shaw LJ, Devereux RB, et al. Prognostic value of multidetector coronary computed tomographic angiography for prediction of allcause mortality. J Am Coll Cardiol 2007;50: 1161–70.

**50.** Hadamitzky M, Täubert S, Deseive S, et al. Prognostic value of coronary computed tomography angiography during 5 years of follow-up in patients with suspected coronary artery disease. Eur Heart J 2013;34:3277-85.

**51.** Task Force Members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013;34:2949–3003.

**52.** Douglas PS, Hoffmann U, Patel MR, et al., PROMISE Investigators. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med 2015;372:1291-300.

**53.** Williams MC, Hunter A, Shah ASV, et al., SCOT-HEART Investigators. Use of coronary computed tomographic angiography to guide management of patients with coronary disease. J Am Coll Cardiol 2016;67:1759-68.

**54.** Bittencourt MS, Hulten EA, Murthy VL, et al. Clinical outcomes after evaluation of stable chest pain by coronary computed tomographic angiography versus usual care: a meta-analysis. Circ Cardiovasc Imaging 2016;9:e004419.

**55.** Goldstein JA, Chinnaiyan KM, Abidov A, et al., CT-STAT Investigators. The CT-STAT (Coronary

Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment) trial. J Am Coll Cardiol 2011;58:1414-22.

**56.** Hoffmann U, Truong QA, Schoenfeld DA, et al., ROMICAT-II Investigators. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med 2012;367:299-308.

**57.** Litt HI, Gatsonis C, Snyder B, et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. N Engl J Med 2012;366:1393-403.

**58.** Hulten E, Pickett C, Bittencourt MS, et al. Outcomes after coronary computed tomography angiography in the emergency department: a systematic review and meta-analysis of randomized, controlled trials. J Am Coll Cardiol 2013;61: 880–92.

**59.** Kim WY, Danias PG, Stuber M, et al. Coronary magnetic resonance angiography for the detection of coronary stenoses. N Engl J Med 2001;345: 1863-9.

**60.** Schuetz GM, Zacharopoulou NM, Schlattmann P, et al. Meta-analysis: noninvasive coronary angiography using computed tomography versus magnetic resonance imaging. Ann Intern Med 2010;152:167-77.

**61.** Yonezawa M, Nagata M, Kitagawa K, et al. Quantitative analysis of 1.5-T whole-heart coronary MR angiograms obtained with 32-channel cardiac coils: a comparison with conventional quantitative coronary angiography. Radiology 2014;271:356-64.

**62.** Hundley WG, Bluemke DA, Finn JP, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2010;55: 2614-62.

**63.** Rochitte CE, George RT, Chen MY, et al. Computed tomography angiography and perfusion to assess coronary artery stenosis causing perfusion defects by single photon emission computed tomography: the CORE320 study. Eur Heart J 2014;35:1120-30.

**64.** Pelgrim GJ, Dorrius M, Xie X, et al. The dream of a one-stop-shop: meta-analysis on myocardial perfusion CT. Eur J Radiol 2015;84:2411-20.

**65.** Koo BK, Erglis A, Doh JH, et al. Diagnosis of ischemia-causing coronary stenoses by noninvasive fractional flow reserve computed from coronary computed tomographic angiograms. Results from the prospective multicenter DISCOVER-FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve) study. J Am Coll Cardiol 2011;58:1989–97.

**66.** Min JK, Leipsic J, Pencina MJ, et al. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA 2012;308:1237-45.

**67.** Li S, Tang X, Peng L, et al. The diagnostic performance of CT-derived fractional flow reserve for evaluation of myocardial ischaemia confirmed by invasive fractional flow reserve: a meta-analysis. Clin Radiol 2015;70:476-86.

**68.** Douglas PS, Pontone G, Hlatky MA, et al., PLATFORM Investigators. Clinical outcomes of

fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR(CT): outcome and resource impacts study. Eur Heart J 2015;36:3359–67.

**69.** Schwitter J, Wacker CM, Wilke N, et al., MR-IMPACT Investigators. MR-IMPACT II: Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary artery disease Trial: perfusion-cardiac magnetic resonance vs. single-photon emission computed tomography for the detection of coronary artery disease: a comparative multicentre, multivendor trial. Eur Heart J 2013;34:775-81.

**70.** Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular magnetic resonance and singlephoton emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet 2012;379:453-60.

**71.** Greenwood JP, Herzog BA, Brown JM, et al. Prognostic value of cardiovascular magnetic resonance and single-photon emission computed tomography in suspected coronary heart disease: long-term follow-up of a prospective, diagnostic accuracy cohort study. Ann Intern Med 2016;165: 1-9.

**72.** Jaarsma C, Leiner T, Bekkers SC, et al. Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis. J Am Coll Cardiol 2012; 59:1719-28.

**73.** Coelho-Filho OR, Seabra LF, Mongeon FP, et al. Stress myocardial perfusion imaging by CMR provides strong prognostic value to cardiac events regardless of patient's sex. J Am Coll Cardiol Img 2011;4:850-61.

**74.** Walker S, Girardin F, McKenna C, et al. Costeffectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study. Heart 2013;99:873-81.

**75.** Charoenpanichkit C, Hundley WG. The 20 year evolution of dobutamine stress cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010;12:59.

**76.** Adams DF, Hessel SJ, Judy PF, et al. Computed tomography of the normal and infarcted myocardium. AJR Am J Roentgenol 1976;126:786-91.

**77.** Matsuda T, Kido T, Itoh T, et al. Diagnostic accuracy of late iodine enhancement on cardiac computed tomography with a denoise filter for the evaluation of myocardial infarction. Int J Cardiovasc Imaging 2015;31 Suppl 2:177-85.

**78.** Reimann AJ, Kuettner A, Klumpp B, et al. Late enhancement using multidetector row computer tomography: a feasibility study with low dose 80 kV protocol. Eur J Radiol 2008;66:127-33.

**79.** McCrohon JA, Moon JCC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003;108:54–9. **80.** Kim HW, Farzaneh-Far A, Kim RJ. Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications. J Am Coll Cardiol 2009;55:1-16.

**81.** Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 2013;309:896–908.

**82.** Dweck MR, Joshi S, Murigu T, et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol 2011;58:1271-9.

**83.** Kelle S, Roes SD, Klein C, et al. Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol 2009;54:1770-7.

**84.** Eitel I, de Waha S, Wöhrle J, et al. Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. J Am Coll Cardiol 2014;64:1217-26.

**85.** Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006;113:2733–43.

**86.** Schelbert EB, Cao JJ, Sigurdsson S, et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA 2012; 308:890–6.

87. Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008;118:1011-20.

**88.** Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to

identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-53.

**89.** Beek AM, Kühl HP, Bondarenko O, et al. Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. J Am Coll Cardiol 2003;42:895-901.

**90.** Gutberlet M, Fröhlich M, Mehl S, et al. Myocardial viability assessment in patients with highly impaired left ventricular function: comparison of delayed enhancement, dobutamine stress MRI, end-diastolic wall thickness, and TI201-SPECT with functional recovery after revascularization. Eur Radiol 2005;15:872–80.

**91.** Glaveckaite S, Valeviciene N, Palionis D, et al. Value of scar imaging and inotropic reserve combination for the prediction of segmental and global left ventricular functional recovery after revascularisation. J Cardiovasc Magn Reson 2011; 13:35.

**92.** Knuesel PR, Nanz D, Wyss C, et al. Characterization of dysfunctional myocardium by positron emission tomography and magnetic resonance: relation to functional outcome after revascularization. Circulation 2003;108: 1095-100.

**93.** Shah DJ, Kim HW, James O, et al. Prevalence of regional myocardial thinning and relationship with myocardial scarring in patients with coronary artery disease. JAMA 2013;309:909-18.

**94.** Bonow RO, Maurer G, Lee KL, et al., STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011;364:1617-25.

**95.** Friedrich MG, Abdel-Aty H, Taylor A, et al. The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51: 1581-7. **96.** Ugander M, Oki AJ, Hsu LY, et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and subclinical myocardial pathology. Eur Heart J 2012;33: 1268–78.

**97.** Weinsaft JW, Kim RJ, Ross M, et al. Contrastenhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. J Am Coll Cardiol Img 2009;2:969–79.

**98.** Mollet NR, Dymarkowski S, Volders W, et al. Visualization of ventricular thrombi with contrastenhanced magnetic resonance imaging in patients with ischemic heart disease. Circulation 2002;106: 2873–6.

**99.** Daftari Besheli L, Aran S, Shaqdan K, et al. Current status of nephrogenic systemic fibrosis. Clin Radiol 2014;69:661-8.

**100.** Kanda T, Fukusato T, Matsuda M, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015;276: 228-32.

**101.** U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI). U.S. Food and Drug Administration. July 27, 2015. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm455386. htm. Accessed August 31, 2016.

KEY WORDS acute coronary syndrome, atherosclerosis, calcium, coronary artery disease, myocardial infarction, noninvasive imaging